Should I buy or sell MEI Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares. View MEIP analyst ratings or view top-rated stocks .

What is MEI Pharma's stock price target for 2024?

1 brokerages have issued twelve-month target prices for MEI Pharma's stock. Their MEIP share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 115.4% from the stock's current price. View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts .

How have MEIP shares performed in 2024?

MEI Pharma's stock was trading at $5.80 at the beginning of the year. Since then, MEIP shares have decreased by 44.0% and is now trading at $3.25. View the best growth stocks for 2024 here .

When is MEI Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MEIP earnings forecast .

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings data on Tuesday, February, 13th. The company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.46) by $0.20. MEI Pharma had a trailing twelve-month return on equity of 39.72% and a net margin of 39.06%.

How often does MEI Pharma pay dividends? What is the dividend yield for MEI Pharma?

MEI Pharma announced a dividend on Monday, November 6th. Investors of record on Friday, November 17th will be given a dividend of $1.75 per share on Wednesday, December 6th. The ex-dividend date of this dividend is Thursday, November 16th. Read our dividend analysis for MEIP .

When did MEI Pharma's stock split?

MEI Pharma shares reverse split on the morning of Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO) , Rigel Pharmaceuticals (RIGL) , Gilead Sciences (GILD) , Novavax (NVAX) , Dynavax Technologies (DVAX) , SCYNEXIS (SCYX) , OPKO Health (OPK) , VBI Vaccines (VBIV) , Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD) .

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MEIP

MEI Pharma (MEIP) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free MEIP Stock Alerts

$3.25

-0.06 (-1.81%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.25
▼
$3.38
50-Day Range: $3.19
▼
$4.89
52-Week Range: $3.20
▼
$7.97

Volume: 12,047 shs
Average Volume: 23,294 shs
Market Capitalization: $21.65 million

P/E Ratio: 1.09
Dividend Yield: N/A
Price Target: $7.00

Get MEI Pharma alerts:

MEI Pharma MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 115.4% Upside
$7.00 Price Target
Short Interest: Healthy
0.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: 0.00
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $3.24 to ($4.98) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

150th out of 918 stocks

Pharmaceutical Preparations Industry

51st out of 402 stocks

3.0

Analyst's Opinion

Consensus Rating
MEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
MEI Pharma has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.13% of the float of MEI Pharma has been sold short.
Short Interest Ratio / Days to Cover
MEI Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MEI Pharma has recently decreased by 14.29%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MEI Pharma does not currently pay a dividend.
Dividend Growth
MEI Pharma does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
MEI Pharma has received a 71.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for MEI Pharma is -0.78.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 4 news articles for MEI Pharma this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MEI Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.90% of the stock of MEI Pharma is held by insiders.
Percentage Held by Institutions
52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for MEI Pharma are expected to decrease in the coming year, from $3.24 to ($4.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MEI Pharma is 1.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.19.
Price to Earnings Ratio vs. Sector
The P/E ratio of MEI Pharma is 1.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 254.29.
Price to Book Value per Share Ratio
MEI Pharma has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About MEI Pharma Stock (NASDAQ:MEIP)

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEIP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MEIP Stock News Headlines

April 18, 2024 | insidermonkey.com

5 Cheap Penny Stocks to Buy According to Analysts

April 14, 2024 | americanbankingnews.com

MEI Pharma's (MEIP) "Hold" Rating Reaffirmed at Stifel Nicolaus

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 13, 2024 | americanbankingnews.com

MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com

April 11, 2024 | msn.com

MEI Pharma shelves plans for a second return of capital

April 11, 2024 | businesswire.com

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

April 11, 2024 | businesswire.com

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

April 10, 2024 | businesswire.com

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 26, 2024 | finance.yahoo.com

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

March 20, 2024 | stocknews.com

3 Pharma Stocks Outperforming the Competition

March 3, 2024 | investing.com

MEI Pharma Inc (MEIP)

February 29, 2024 | seekingalpha.com

MEIP MEI Pharma, Inc.

February 15, 2024 | businesswire.com

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

February 15, 2024 | businesswire.com

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

February 13, 2024 | finance.yahoo.com

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

February 13, 2024 | finance.yahoo.com

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

February 13, 2024 | businesswire.com

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

February 8, 2024 | wsj.com

MEI Pharma Inc.

February 8, 2024 | finance.yahoo.com

Is MEI Pharma (MEIP) Attractively Priced?

January 18, 2024 | forbes.com

Acceleron Pharma

January 16, 2024 | finance.yahoo.com

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

December 27, 2023 | benzinga.com

MEI Pharma Stock (NASDAQ:MEIP), Short Interest Report

December 27, 2023 | benzinga.com

MEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and Dates

December 11, 2023 | finance.yahoo.com

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

November 16, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)

November 14, 2023 | morningstar.com

MEI Pharma Inc MEIP

See More Headlines

Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MEIP
Previous Symbol: NASDAQ:MSHL
CUSIP: N/A
CIK: 1262104
Web: www.meipharma.com
Phone: (858) 369-7100
Fax: 302-655-5049
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +115.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.97
Trailing P/E Ratio: 1.09
Forward P/E Ratio: 1.00
P/E Growth: N/A
Net Income: $-31,840,000.00
Net Margins: 39.06%
Pretax Margin: 27.32%
Return on Equity: 39.72%
Return on Assets: 18.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.23
Quick Ratio: 8.23

Sales & Book Value

Annual Sales: $48.82 million
Price / Sales: 0.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.70 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 6,660,000
Free Float: 6,403,000
Market Cap: $21.65 million
Optionable: Optionable
Beta: 0.77

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. David M. Urso B.A. (Age 60)
Esq., J.D., CEO, President & Director
Comp: $748.46k
Dr. Richard G. Ghalie M.D. (Age 66)
MBA, Chief Medical Officer
Comp: $627.76k
Mr. Justin J. File (Age 54)
CFO & Corporate Secretary
Ms. Yomara Gomez-Naiden
Senior Vice President of Operations & Quality
Ms. Nicole Chyoko Iida
Vice President of Legal Affairs
Ms. Anne Frese
Chief People Officer
Dr. Robert D. Mass (Age 70)
Strategic Advisor
Comp: $201.68k
Mr. David A. Walsey J.D.
L.L.M., Senior Vice President of Corporate Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MEIP Stock Analysis - Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings or view top-rated stocks.
What is MEI Pharma's stock price target for 2024?: 1 brokerages have issued twelve-month target prices for MEI Pharma's stock. Their MEIP share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 115.4% from the stock's current price.
View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts.
How have MEIP shares performed in 2024?: MEI Pharma's stock was trading at $5.80 at the beginning of the year. Since then, MEIP shares have decreased by 44.0% and is now trading at $3.25.
View the best growth stocks for 2024 here.
When is MEI Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MEIP earnings forecast.
How were MEI Pharma's earnings last quarter?: MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings data on Tuesday, February, 13th. The company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.46) by $0.20. MEI Pharma had a trailing twelve-month return on equity of 39.72% and a net margin of 39.06%.

How often does MEI Pharma pay dividends? What is the dividend yield for MEI Pharma?: MEI Pharma announced a dividend on Monday, November 6th. Investors of record on Friday, November 17th will be given a dividend of $1.75 per share on Wednesday, December 6th. The ex-dividend date of this dividend is Thursday, November 16th.
Read our dividend analysis for MEIP.
When did MEI Pharma's stock split?: MEI Pharma shares reverse split on the morning of Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of MEI Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).
How do I buy shares of MEI Pharma?: Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEIP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MEI Pharma (MEIP) Stock Price, News & Analysis

MEI Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MEI Pharma Stock (NASDAQ:MEIP)

MEIP Stock Price History

MEIP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MEIP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™